But with Derm Assist available free, how will the company make money?
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
The Verily subsidiary has the luxury of patient backers. But hungrier rivals could steal a march.
The deal is a late entrant into 2020's top five mergers and acquisitions.
Digital therapeutics are going from strength to strength during the pandemic.
Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?
Software-enabled medical devices pose unique challenges to regulators, and the US agency is getting serious about meeting them.
Licensing deal could enable bundling of antipsychotics with management technology.